Armodafinil in the treatment of excessive sleepiness

Bibliography

• National Sleep Foundation. 2008 Sleep in America Poll. National Sleep Foundation, Washington, DC; 2008. Available from: http://www.sleepfoundation.org/category/ article-type/sleep-america-polls. [Last accessed 1 November 2009]
   Google Scholar
• National Sleep Foundation. 2009 Sleep in America Poll. National Sleep Foundation, Washington, DC; 2009. Available from: http://www.sleepfoundation.org/category/ article-type/sleep-america-polls. [Last accessed 1 November 2009]
   Google Scholar
• Black J, Duntley SP, Bogan RK, O'Malley MB. Recent advances in the treatment and management of excessive daytime sleepiness. CNS Spectr 2007;12:1-14
   PubMed Web of Science ®Google Scholar
• Young T, Palta M, Dempsey J, The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230-5
   PubMed Web of Science ®Google Scholar
• Weaver TE, Maislin G, Dinges DF, Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep 2007;30:711-19
   PubMed Web of Science ®Google Scholar
• Richardson GS. The human circadian system in normal and disordered sleep. J Clin Psychiatry 2005;66(Suppl 9):3-9
   PubMedGoogle Scholar
• Schwartz JR, Roth T. Shift work sleep disorder: burden of illness and approaches to management. Drugs 2006;66:2357-70
   PubMed Web of Science ®Google Scholar
• Eastman CI, Stewart KT, Mahoney MP, Dark goggles and bright light improve circadian rhythm adaptation to night-shift work. Sleep 1994;17:535-43
   PubMed Web of Science ®Google Scholar
• Morgenthaler TI, Lee-Chiong T, Alessi C, Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report. Sleep 2007;30:1445-59
   PubMed Web of Science ®Google Scholar
• Drake CL, Roehrs T, Richardson G, Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep 2004;27:1453-62
   PubMed Web of Science ®Google Scholar
• Waage S, Moen BE, Pallesen S, Shift work disorder among oil rig workers in the North Sea. Sleep 2009;32:558-65
   PubMed Web of Science ®Google Scholar
• Bogan R, Tiller J, Youakim J, Roth T. Armodafinil for excessive sleepiness associated with jet lag disorder. Sleep 2009;32(Suppl):A52
   Google Scholar
• Morgenthaler TI, Kapen S, Lee-Chiong T, Practice parameters for the medical therapy of obstructive sleep apnea. Sleep 2006;29:1031-5
   PubMed Web of Science ®Google Scholar
• Morgenthaler TI, Kapur VK, Brown T, Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007;30:1705-11
   PubMed Web of Science ®Google Scholar
• US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97
   PubMed Web of Science ®Google Scholar
• US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166-75
   PubMed Web of Science ®Google Scholar
• Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005;1:391-7
   PubMedGoogle Scholar
• US Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25:42-9
   PubMed Web of Science ®Google Scholar
• US Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119-23
   PubMed Web of Science ®Google Scholar
• Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005;6:415-21
   PubMed Web of Science ®Google Scholar
• Schwartz JR, Hirshkowitz M, Erman MK, Schmidt-Nowara W. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study. Chest 2003;124:2192-9
   PubMed Web of Science ®Google Scholar
• Czeisler CA, Walsh JK, Roth T, Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med 2005;353:476-86
   PubMed Web of Science ®Google Scholar
• Erman MK, Rosenberg R, for the US Modafinil Shift Work Sleep Disorder Study Group. Modafinil for excessive sleepiness associated with chronic shift work sleep disorder: effects on patient functioning and health-related quality of life. Prim Care Companion J Clin Psychiatry 2007;9:188-94
   PubMedGoogle Scholar
• Coste O, Lagarde D. Clinical management of jet lag: what can be proposed when performance is critical? Travel Med Infect Dis 2009;7:82-7
   PubMed Web of Science ®Google Scholar
• Rajaratnam SM, Polymeropoulos MH, Fisher DM, Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 2009;373:482-91
   PubMed Web of Science ®Google Scholar
• Cephalon Inc. NUVIGIL™ (armodafinil) tablets (C-IV). Frazer, PA: Cephalon, Inc., 2008. Available from: http://www.nuvigil.com/media/Full_Prescribing_Information.pdf. [Last accessed 23 September 2009]
   Google Scholar
• Beck P, Odle A, Wallace-Huitt T, Modafinil increases arousal determined by P13 potential amplitude: an effect blocked by gap junction antagonists. Sleep 2008;31:1647-54
   PubMed Web of Science ®Google Scholar
• Urbano FJ, Leznik E, Llinas RR. Modafinil enhances thalamocortical activity by increasing neuronal electrotonic coupling. Proc Natl Acad Sci U S A 2007;104:12554-9
   PubMed Web of Science ®Google Scholar
• Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A 1996;93:14128-33
   PubMed Web of Science ®Google Scholar
• Scammell TE, Estabrooke IV, McCarthy MT, Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000;20:8620-8
   PubMed Web of Science ®Google Scholar
• Fiocchi EM, Lin YG, Aimone L, Armodafinil promotes wakefulness and activates Fos in rat brain. Pharmacol Biochem Behav 2009;92:549-57
   PubMedGoogle Scholar
• Cirelli C, Tononi G. On the functional significance of c-fos induction during the sleep-waking cycle. Sleep 2000;23:453-69
   PubMed Web of Science ®Google Scholar
• España RA, Scammell TE. Sleep neurobiology for the clinician. Sleep 2004;27:811-20
   PubMed Web of Science ®Google Scholar
• Wisor JP, Dement WC, Aimone L, Armodafinil, the R-enantiomer of modafinil: wake-promoting effects and pharmacokinetic profile in the rat. Pharmacol Biochem Behav 2006;85:492-9
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Hellriegel ET, Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies. Clin Drug Investig 2009;29:87-100
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Hellriegel ET, Robertson P Jr. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. Clin Drug Investig 2009;29:613-23
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Hellriegel ET. Comparison of steady-state plasma concentrations of armodafinil and modafinil late in the day following morning administration: post hoc analysis of two randomized, double-blind, placebo-controlled, multiple-dose studies in healthy male subjects. Clin Drug Investig 2009;29:601-12
   PubMed Web of Science ®Google Scholar
• Robertson PJ, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003;42:123-37
   PubMed Web of Science ®Google Scholar
• Wong YN, King SP, Simcoe D, Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 1999;39:281-8
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Robertson PJ, Hellriegel ET. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet 2008;47:61-74
   PubMed Web of Science ®Google Scholar
• Dinges DF, Arora S, Darwish M, Niebler GE. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin 2006;22:159-67
   PubMed Web of Science ®Google Scholar
• Hirshkowitz M, Black JE, Wesnes K, Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnoea/hypopnoea syndrome. Respir Med 2007;101:616-27
   PubMed Web of Science ®Google Scholar
• Roth T, Rippon GA, Arora S. Armodafinil improves wakefulness and long-term episodic memory in nCPAP-adherent patients with excessive sleepiness associated with obstructive sleep apnea. Sleep Breath 2008;12:53-62
   PubMed Web of Science ®Google Scholar
• Harsh JR, Hayduk R, Rosenberg R, The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006;22:761-74
   PubMed Web of Science ®Google Scholar
• Roth T, White D, Schmidt-Nowara W. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCAP-adherent adults. Clin Ther 2006;28:689-706
   PubMed Web of Science ®Google Scholar
• Czeisler CA, Walsh JK, Wesnes KA, Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study. Mayo Clin Proc 2009;84:958-72
   PubMed Web of Science ®Google Scholar
• Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK. The cognitive drug research computerized assessment system for demented patients: a validation study. Int J Geriatr Psychiatry 1991;6:95-102
   Web of Science ®Google Scholar
• Cephalon, Inc. PROVIGIL^® (modafinil) tablets. Frazer, PA Cephalon, Inc., 2007. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020717s020s013s018lbl.pdf. [Last accessed 28 September 2009]
   Google Scholar
• National Institutes of Health. ClinicalTrials.gov. US National Library of Medicine, Bethesda, MD; 2009. Available from: www.clinicaltrials.gov. [Last accessed 14 December 2009]
   Google Scholar
• Bixler EO, Vgontzas AN, Lin HM, Excessive daytime sleepiness in a general population sample: the role of sleep apnea, age, obesity, diabetes, and depression. J Clin Endocrinol Metab 2005;90:4510-15
   PubMed Web of Science ®Google Scholar
• Newman AB, Foster G, Givelber R, Progression and regression of sleep-disordered breathing with changes in weight: the Sleep Heart Health Study. Arch Intern Med 2005;165:2408-13
   PubMed Web of Science ®Google Scholar
• Elwood P, Hack M, Pickering J, Sleep disturbance, stroke, and heart disease events: evidence from the Caerphilly cohort. J Epidemiol Community Health 2006;60:69-73
   PubMed Web of Science ®Google Scholar
• Leger D. The cost of sleep-related accidents: a report for the National Commission on Sleep Disorders Research. Sleep 1994;17:84-93
   PubMed Web of Science ®Google Scholar
• Flatley D, Reyner LA, Horne JA. Sleep-related crashes on sections of different road types in the UK (1995–2001). Report no. 52. Department of Transport, Road Safety Research, London; 2004
   Google Scholar